FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY)
Aim. To assess five-year trend in terms of specialists’ adherence to guidelines on secondary prevention of cardiovascular diseases in patients with stable angina on the level of out-patient specialized healthcare institution in Moscow.Material and methods. Two-stage retrospective pharmacoepidemiolog...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2018-05-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1655 |
| _version_ | 1797232138100146176 |
|---|---|
| author | S. В. Fitilev I. I. Shkrebneva A. V. Vozzhaev K. O. Tsukanova |
| author_facet | S. В. Fitilev I. I. Shkrebneva A. V. Vozzhaev K. O. Tsukanova |
| author_sort | S. В. Fitilev |
| collection | DOAJ |
| description | Aim. To assess five-year trend in terms of specialists’ adherence to guidelines on secondary prevention of cardiovascular diseases in patients with stable angina on the level of out-patient specialized healthcare institution in Moscow.Material and methods. Two-stage retrospective pharmacoepidemiological study was conducted. The object of the study – patient medical records. At the first stage of the study medical records of 2915 patients with stable angina visited the healthcare institution for the first time in 2006 were included, at the second stage – medical records of 1633 patients with stable angina with primary visit in 2011.Results. Over the five-year period prescription rates of drugs improving prognosis in patients with stable angina significantly increased: antiplatelets – up to 82.7%, beta-blockers – up to 74.3%, statins – up to 45.6%. Despite of no changes registered in prescription rate of the ACE inhibitors, marked increase up to 14.7% in prescription rate of angiotensin receptor blockers was revealed. In the prescription structure of pharmacological groups changes were detected concerning the preferred choice of a specific drug. Due to implementation of dual antiplatelet therapy into clinical practice a reduced number of recommendations of acetylsalicylic acid as monotherapy (down to 93.0%) and increased – in combination with clopidogrel (up to 5.4%) was registered at the second stage of the study. Over a five-year period bisoprolol (55.0%) occupied the leading position in the group of beta-blockers. Metoprolol’s prescription rate decreased to 27.4%. Prescription rate of atenolol decreased down to 3.1%, while that of nebivolol increased up to 8.3%. When choosing among statins specialists recommended significantly more often atorvastatin (up to 52.9%). In the group of ACE inhibitors three drugs preserved their leading positions. Meanwhile the number of recommendations of enalapril increased up to 50.8%, perindopril – up to 24.1%. Analysis of prescribed doses revealed significant increase in recommendations of specific drugs in higher daily doses: acetylsalicylic acid 100 mg – up to 71.1%, simvastatin and atorvastatin 20 mg – up to 60.5% and 41.9%, respectively. When prescribing beta-blockers and ACE inhibitors specialists continued to use minimal and medium therapeutic doses, possibly due to dose titration in patients with comorbidities.Conclusion. Study results demonstrated positive trend in terms of specialists’ adherence to guidelines on secondary prevention of cardiovascular diseases in patients with stable angina. However, a number of problem aspects were identified that require further optimization of medical and preventive measures in healthcare institutions. |
| first_indexed | 2024-03-08T14:01:48Z |
| format | Article |
| id | doaj.art-23512af46bf748aead39b6d5e42f61ec |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:55:30Z |
| publishDate | 2018-05-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-23512af46bf748aead39b6d5e42f61ec2024-04-01T07:43:36ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532018-05-0114224425110.20996/1819-6446-2018-14-2-244-2511467FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY)S. В. Fitilev0I. I. Shkrebneva1A. V. Vozzhaev2K. O. Tsukanova3Peoples' Friendship University of Russia (RUDN University)Peoples' Friendship University of Russia (RUDN University)Peoples' Friendship University of Russia (RUDN University)Peoples' Friendship University of Russia (RUDN University)Aim. To assess five-year trend in terms of specialists’ adherence to guidelines on secondary prevention of cardiovascular diseases in patients with stable angina on the level of out-patient specialized healthcare institution in Moscow.Material and methods. Two-stage retrospective pharmacoepidemiological study was conducted. The object of the study – patient medical records. At the first stage of the study medical records of 2915 patients with stable angina visited the healthcare institution for the first time in 2006 were included, at the second stage – medical records of 1633 patients with stable angina with primary visit in 2011.Results. Over the five-year period prescription rates of drugs improving prognosis in patients with stable angina significantly increased: antiplatelets – up to 82.7%, beta-blockers – up to 74.3%, statins – up to 45.6%. Despite of no changes registered in prescription rate of the ACE inhibitors, marked increase up to 14.7% in prescription rate of angiotensin receptor blockers was revealed. In the prescription structure of pharmacological groups changes were detected concerning the preferred choice of a specific drug. Due to implementation of dual antiplatelet therapy into clinical practice a reduced number of recommendations of acetylsalicylic acid as monotherapy (down to 93.0%) and increased – in combination with clopidogrel (up to 5.4%) was registered at the second stage of the study. Over a five-year period bisoprolol (55.0%) occupied the leading position in the group of beta-blockers. Metoprolol’s prescription rate decreased to 27.4%. Prescription rate of atenolol decreased down to 3.1%, while that of nebivolol increased up to 8.3%. When choosing among statins specialists recommended significantly more often atorvastatin (up to 52.9%). In the group of ACE inhibitors three drugs preserved their leading positions. Meanwhile the number of recommendations of enalapril increased up to 50.8%, perindopril – up to 24.1%. Analysis of prescribed doses revealed significant increase in recommendations of specific drugs in higher daily doses: acetylsalicylic acid 100 mg – up to 71.1%, simvastatin and atorvastatin 20 mg – up to 60.5% and 41.9%, respectively. When prescribing beta-blockers and ACE inhibitors specialists continued to use minimal and medium therapeutic doses, possibly due to dose titration in patients with comorbidities.Conclusion. Study results demonstrated positive trend in terms of specialists’ adherence to guidelines on secondary prevention of cardiovascular diseases in patients with stable angina. However, a number of problem aspects were identified that require further optimization of medical and preventive measures in healthcare institutions.https://www.rpcardio.online/jour/article/view/1655secondary preventionstable anginaantiplateletsstatinsace inhibitorsbeta-blockerspharmacoepidemiology |
| spellingShingle | S. В. Fitilev I. I. Shkrebneva A. V. Vozzhaev K. O. Tsukanova FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) Рациональная фармакотерапия в кардиологии secondary prevention stable angina antiplatelets statins ace inhibitors beta-blockers pharmacoepidemiology |
| title | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) |
| title_full | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) |
| title_fullStr | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) |
| title_full_unstemmed | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) |
| title_short | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) |
| title_sort | five year dynamics of secondary prevention in patients with stable angina at specialized out patient level in moscow pharmacoepidemiology study |
| topic | secondary prevention stable angina antiplatelets statins ace inhibitors beta-blockers pharmacoepidemiology |
| url | https://www.rpcardio.online/jour/article/view/1655 |
| work_keys_str_mv | AT svfitilev fiveyeardynamicsofsecondarypreventioninpatientswithstableanginaatspecializedoutpatientlevelinmoscowpharmacoepidemiologystudy AT iishkrebneva fiveyeardynamicsofsecondarypreventioninpatientswithstableanginaatspecializedoutpatientlevelinmoscowpharmacoepidemiologystudy AT avvozzhaev fiveyeardynamicsofsecondarypreventioninpatientswithstableanginaatspecializedoutpatientlevelinmoscowpharmacoepidemiologystudy AT kotsukanova fiveyeardynamicsofsecondarypreventioninpatientswithstableanginaatspecializedoutpatientlevelinmoscowpharmacoepidemiologystudy |